Guihong Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guihong Lu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Fan Zhang
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, PR China
3 shared publications - Li-Li Huang
School of Medical Technology, Beijing Institute of Technology, Beijing 100081, PR China
3 shared publications Ruiqi Ming
School of Medical Technology, Beijing Institute of Technology, Beijing 100081, PR China
3 shared publicationsShujun Liu
School of Medical Technology, Beijing Institute of Technology, Beijing 100081, PR China
3 shared publicationsZhongjie Wang
School of Medical Technology, Beijing Institute of Technology, Beijing 100081, PR China
3 shared publicationsChenguang Wang
School of Medical Technology, Beijing Institute of Technology, Beijing 100081, PR China
2 shared publications
Latest Publications
- 5 May 2026
- Published by Elsevier in Biomaterials
- Vol. 334, 124279
Spleen-tumor dual-targeting vaccines reshape anticancer landscape by activating both innate and adaptive immunity
- 5 May 2026
- Published by Elsevier in Biomaterials
- Vol. 334, 124279
Spleen-tumor dual-targeting vaccines reshape anticancer landscape by activating both innate and adaptive immunity
- 28 October 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 388 (Pt 2) , 114358
Spatiotemporal STING activation via engineered bacterial vesicles enables safe and efficient cancer immunotherapy
- 28 October 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 388 (Pt 2) , 114358
Spatiotemporal STING activation via engineered bacterial vesicles enables safe and efficient cancer immunotherapy
- Open Access
- 27 February 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-13
A self-adjuvant multiantigenic nanovaccines simultaneously activate the antiviral and antitumor immunity for the treatment of cancers
Tumor cell-derived extracellular vesicles (tEVs) have garnered significant attention as promising antigen delivery vehicles for the development of cancer vaccines. However, their practical applications are hindered by weak immunogenicity and inadequate lymph node targeting. In this study, we engineered tEVs into “self-adjuvant” multiantigenic nanovaccines that simultaneously accumulate in tumors and lymph nodes (LNs), effectively triggering innate and adaptive immunity capable of recognizing both tumor cells and virus antigen-modified tumor cells to inhibit tumor progression. 4T1 tumor cells were infected with vesicular stomatitis virus (VSV), leading to the expression of VSVG and calreticulin (CRT) on their surface. Using these infected cells, we prepared extracellular vesicles (vEVs) carrying both VSVG and CRT. When injected subcutaneously, vEVs targeted tumors effectively due to the homologous targeting capability of tumor cell membranes. In which, VSVG induced fusion between vEVs and tumor cells, creating viral antigen-decorated tumor cells, which enhanced the recognition and phagocytosis of tumor cells by macrophages. Additionally, the surface CRT of vEVs activated the “eat-me” signaling, thus improving their recognition and uptake by dendritic cells (DCs). This led to DC maturation and the activation of antiviral and antitumor T cells, synergistically inhibiting tumor growth. This research introduces a straightforward yet efficacious methodology for the production of cancer vaccines to fight cancer through the stimulation of both the antiviral and antitumor immune responses within the body.
- 27 February 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-13
Open AccessA self-adjuvant multiantigenic nanovaccines simultaneously activate the antiviral and antitumor immunity for the treatment of cancers
Tumor cell-derived extracellular vesicles (tEVs) have garnered significant attention as promising antigen delivery vehicles for the development of cancer vaccines. However, their practical applications are hindered by weak immunogenicity and inadequate lymph node targeting. In this study, we engineered tEVs into “self-adjuvant” multiantigenic nanovaccines that simultaneously accumulate in tumors and lymph nodes (LNs), effectively triggering innate and adaptive immunity capable of recognizing both tumor cells and virus antigen-modified tumor cells to inhibit tumor progression. 4T1 tumor cells were infected with vesicular stomatitis virus (VSV), leading to the expression of VSVG and calreticulin (CRT) on their surface. Using these infected cells, we prepared extracellular vesicles (vEVs) carrying both VSVG and CRT. When injected subcutaneously, vEVs targeted tumors effectively due to the homologous targeting capability of tumor cell membranes. In which, VSVG induced fusion between vEVs and tumor cells, creating viral antigen-decorated tumor cells, which enhanced the recognition and phagocytosis of tumor cells by macrophages. Additionally, the surface CRT of vEVs activated the “eat-me” signaling, thus improving their recognition and uptake by dendritic cells (DCs). This led to DC maturation and the activation of antiviral and antitumor T cells, synergistically inhibiting tumor growth. This research introduces a straightforward yet efficacious methodology for the production of cancer vaccines to fight cancer through the stimulation of both the antiviral and antitumor immune responses within the body.
- 20 December 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 378, 416-427
Engineered virus-mimicking nanovaccine with lymph node–tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy
- 20 December 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 378, 416-427
Engineered virus-mimicking nanovaccine with lymph node–tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy